Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients

NCT05101213 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05101213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05101213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
January 6, 2023
Completion date
August 3, 2026
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenovirus infection, bk virus infection, cytomegaloviral infection, hematopoietic and lymphoid cell neoplasm, jc virus infection, malignant solid neoplasm, symptomatic covid-19 infection laboratory-confirmed